Now approved: new ALS treatment option for your members 96 ================================================================================================================================= we need 1k of characters in the head to prevent iOS devices from displaying the "download rest of message"... message... ************************************************************************************************************…
Effective October 1, 2022: J1932: A unique HCPCS code for Cipla's Lanreotide Depot Effective October 1, 2022: J1932, injection, lanreotide, (Cipla), 1 mg, is available for all sites of care. J1932 is a unique HCPCS code for Cipla's version of Lanreotide Depot and should not be used for billing other lanreotide formulations. HCPCS Code HCPCS Code Descriptor NDC Number How Supplied ASP Per HCPCS Unit (1 mg) HCPCS Units Per Package…
Effective October 1, 2022: J9274, Injection, tebentafusp-tebn, 1 microgram for KIMMTRAK® Effective For Dates of Service Beginning October 1, 2022 KIMMTRAK Permanent J-Code Now Available J9274 Injection, tebentafusp-tebn, 1 microgram KIMMTRAK Coding Details: HCPCS Code HCPCS Code Description NDC NDC Description HCPCS Units Per Package WAC* Per HCPCS Unit J9274 Injection, tebentafusp-tebn, 1 mcg 80446-0401-01 Single Dose Vial Containing…
Announcing A Permanent J-Code for a BMS Oncology Product J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg EFFECTIVE FOR DATES OF SERVICE ON OR AFTER OCTOBER 1, 2022: The following HCPCS code may be used to identify OPDUALAG™ (nivolumab and relatlimab-rmbw) J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg Opdualag is a fixed-dose combination: a co-formulation of…
New indication, now approved: ENHERTU® (fam-trastuzumab deruxtecan-nxki) New indication, now approved: ENHERTU® (fam-trastuzumab deruxtecan-nxki) 96 Find out about this new treatment option. Review the PI and Boxed WARNINGS here. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) is NOW APPROVED for the treatment of unresectable or metastatic activating HER2 -mutant 2L non-small cell lung cancer (NSCLC) INDICATION ENHERTU is a HER2-directed…
Coming Soon: A Permanent J-code (J2777) for VABYSMO® Coming Soon: A Permanent J-code (J2777) for VABYSMO ® effective for services beginning October 1, 2022 A permanent J-code will go into effect for dates of service beginning October 1, 2022. J2777: Injection, faricimab-svoa, 0.1 mg Please ensure your systems are updated to accept J2777 for VABYSMO for services starting October 1, 2022 VABYSMO NDC Code 50242-0096-01: VABYSMO (6…
Announcing a new Wholesale Acquisition Cost (WAC) for NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Announcing a New WAC for NEXPLANON Effective August 18, 2022, the new WAC for NEXPLANON WAC is $1,092.48. Please update your claims processing system and any applicable fee schedules for NEXPLANON as soon as possible. The price has been communicated to pricing services. HCPCS Labeler 10 Digit NDC 11 Digit NDC Package Description WAC…
96 J9273 Now Available preheader__here --> J-Code J9273. Effective April 1, 2022. Tivdak (tisotumab vedotin-tftv, for injection 40 mg) has been issued a permanent J-code: J9273 . See Indication, BOXED WARNING, and Important Safety Information below. Indication TIVDAK is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This indication is approved…
Permanent J-Code now available for this product 96 ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ Having trouble reading this email? Click here . This email was funded and developed by ViiV Healthcare.
No alerts match your filters.
The Comparative Report puts ASP, the Medicare payment limit, WAC and AWP for up to 15 drugs on one timeline. Ten-plus years of monthly history, per HCPCS unit.
Included with BuyandBill Pro for $37/month billed annually.
Trastuzumab class, seven products
Actual published ASP, Jan 2015 to Aug 2026.